Core Viewpoint - Mission has announced a definitive agreement to acquire Calavo, indicating a strategic move to enhance its market position and operational capabilities [2]. Group 1: Acquisition Details - The acquisition of Calavo is expected to strengthen Mission's portfolio and expand its operational reach [2]. - A press release and presentation regarding the acquisition have been made available online under the Investor Relations section of both companies' websites [3]. Group 2: Forward-Looking Statements - The comments made during the call and the accompanying presentation include forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995 [3][4]. - These forward-looking statements are based on management's current expectations and beliefs, along with various assumptions about future events [4].

Investor Relations Presentation J.P. Morgan 2026 Healthcare Conference Gary Owens, President and CEO John Sakys, CFO Safe Harbor Statement The information provided in this presentation contains forward-looking statements within the meaning of the federal securities laws. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements, including statements relating to: projections of revenues, growth, operating results, profit margins, expenses, earni ...

NASDAQ: BBCP INVESTOR PRESENTATION | January 2026 Disclaimer Forward-Looking Statements This investor presentation includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. The Company's actual results may differ from expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "f ...

Core Viewpoint - AstroNova is engaging with investors to discuss its recent earnings release and performance outlook [2][3]. Group 1: Company Overview - The conference call is led by Deborah Pawlowski, with participation from the CEO Jorik Ittmann and CFO Tom DeByle [3]. - The earnings release and accompanying slides are available on the company's Investor Relations website [3]. Group 2: Financial Performance - Management will discuss forward-looking statements regarding the company's plans and expectations, which are subject to various risks and uncertainties [4]. - Non-GAAP financial measures will be referenced to provide additional insights into the company's performance [5].

Core Viewpoint - Ingevity is conducting a Strategic Portfolio update to discuss future events and financial performance, emphasizing the importance of non-GAAP financial measures in their analysis [2][3]. Group 1: Presentation Overview - The presentation is led by John Nypaver, the VP of Investor Relations and Treasurer, who welcomes attendees to the update [1]. - The discussion will include insights from key executives: Dave Li (CEO), Mary Hall (CFO), and Phil Platt (incoming CFO and current SVP of Finance) [4]. Group 2: Financial Measures - The company will refer to non-GAAP financial measures during the presentation, which are intended to supplement GAAP measures [2]. - Definitions and reconciliations of these non-GAAP measures are available in the appendix of the slide deck and the most recent Form 10-K [2]. Group 3: Forward-Looking Statements - The presentation will include forward-looking statements regarding the company's future events and financial performance, with a caution that actual results may differ from projections [3].

Financial Performance - Total net revenues reached RMB3,208.3 million[17] in 2025Q3, compared to RMB1,444 million[52] in 2023Q3 and RMB3,541 million[52] in 2024Q3 - Non-GAAP net income was RMB502.8 million[18] in 2025Q3, versus RMB306 million[55] in 2023Q3 and RMB503 million[55] in 2024Q3 - As of September 30, 2025, cash and cash equivalents, restricted cash, and time deposits amounted to RMB9,142 million[74] - Net cash provided by operating activities for the three months ended September 30, 2025, was RMB456 million[74] Store Expansion - The company's global teahouse footprint reached 7,338 teahouses[19] by the end of 2025Q3 - There was a net increase of 300 teahouses[19] (QoQ) - Teahouses in Greater China increased by 246[23] (QoQ), while those outside Greater China increased by 54[23] (QoQ) - Expansion included new markets, with 8 teahouses in Vietnam[23] and 3 in the Philippines[23] Customer Engagement - Cumulative registered members reached 222.0 million[37] as of September 30, 2025, representing a 36.7%[36] YoY increase and a 15.0 million[36] net increase QoQ - Third-party delivery platform GMV mix was 57.8%[36] for the three months ended September 30, 2025 Revenue Breakdown - In 2025Q3, franchised teahouses contributed RMB2,812 million[65] to total net revenues, while company-owned teahouses contributed RMB397 million[65]

Core Viewpoint - BingEx Limited, operating under the brand "FlashEx," reported a decline in revenues and order volume for Q3 2025, primarily due to intensified market competition, while also highlighting efforts to enhance brand reputation and customer loyalty [1][3][4]. Financial Performance - Revenues for Q3 2025 were RMB1,005.4 million (US$141.2 million), down from RMB1,154.8 million in Q3 2024, reflecting a decrease of approximately 12.9% [4][6]. - Cost of revenues decreased to RMB893.6 million (US$125.5 million) from RMB1,024.5 million in the same period of 2024, aligning with the revenue decline [4][6]. - Gross profit was RMB111.8 million (US$15.7 million), compared to RMB130.3 million in Q3 2024, with a gross profit margin of 11.1%, slightly down from 11.3% [5][6]. - Operating income fell to RMB14.1 million (US$2.0 million) from RMB46.2 million in Q3 2024, while non-GAAP operating income was RMB23.7 million (US$3.3 million) [6][8]. - Net income increased to RMB43.7 million (US$6.1 million) from RMB23.8 million in the same period of 2024, with non-GAAP net income rising to RMB62.6 million (US$8.8 million) from RMB57.6 million [10][11]. Shareholder Value - Shareholders' equity grew from RMB747.1 million at the end of 2024 to RMB839.3 million as of September 30, 2025 [3][10]. - The company repurchased approximately 1.6 million American Depositary Shares (ADSs) for about US$5.4 million as part of its share repurchase program [3][12]. Operational Insights - The number of orders fulfilled in Q3 2025 was 63.2 million [6]. - General and administrative expenses increased by 105.2% to RMB37.0 million (US$5.2 million) due to higher professional fees and share-based compensation [7]. - Research and development expenses decreased by 20.1% to RMB17.7 million (US$2.5 million) [8]. Market Positioning - The company emphasized its commitment to enhancing competitiveness and expanding service categories to meet evolving user needs, aiming for sustainable growth while fulfilling social responsibilities [3][15].

Financial Targets and Growth - Bausch + Lomb projects a constant currency revenue CAGR of 5-7% from 2025-2028[18] - The company aims for an adjusted EBITDA margin of approximately 23% by 2028, excluding acquired IPR&D, representing a 600 bps increase from 2025[18, 38] - Bausch + Lomb targets double-digit adjusted EPS growth from 2026-2028, excluding acquired IPR&D[18] - The company anticipates an adjusted cash flow from operations to adjusted EBITDA conversion of approximately 50% in 2028[18] - Bausch + Lomb aims to reduce net leverage to approximately 35x by the end of 2028[18] Pipeline and Innovation - The company's pipeline has a potential peak sales of approximately $7 billion[40] - AREDS3 vitamins are expected to expand the AMD market, with a franchise peak sales of approximately $600 million[50] - Lumify Luxe, with enhanced comfort, is projected to have franchise peak sales of approximately $450 million[50] - A dual-action DED eye drop is expected to launch in approximately 2029, with peak sales of approximately $07 billion[55] - A first neurosensory agent for OSP is expected to launch in approximately 2030, with peak sales of approximately $14 billion[55]

Financial Data and Key Metrics Changes - Consolidated total revenue for Q3 2025 was $347.1 million, an increase of 43.3% compared to $242.2 million in the prior year period [16] - Net loss attributable to common stockholders decreased to $9.4 million, or $0.71 per fully diluted share, compared to $15.3 million, or $1.18 per fully diluted share in the prior year [16] - Total adjusted EBITDA was $19.8 million in Q3 2025, up from $16.8 million in the prior year period [16][17] Business Line Data and Key Metrics Changes - Infrastructure segment revenue increased by 45.4% to $338.4 million from $232.8 million in the prior year quarter, driven by project timing and size at DBM Global [17] - DBM Global achieved adjusted EBITDA of $23.5 million, up from $20.9 million in the prior year [18] - Life sciences revenue increased by 3.3% to $3.1 million, primarily driven by R2's sales growth [19][20] - Spectrum segment revenue decreased by $800,000 to $5.6 million, with adjusted EBITDA down by $700,000 to $1 million [21] Market Data and Key Metrics Changes - DBM Global's adjusted backlog increased by approximately $500 million to just over $1.6 billion since the end of 2024 [7] - R2's year-to-date revenues increased by approximately 65% over the same period from last year, with significant growth in international markets [11] - Spectrum faced a challenging advertising environment, but new network launches are showing signs of strength in Q4 [15] Company Strategy and Development Direction - The company is exploring strategic alternatives for DBM Global and HC2 Broadcasting, indicating a focus on optimizing asset value [5] - There is a commitment to exiting life science businesses, although this process has taken longer than expected [5] - The company is focused on enhancing its infrastructure and data center capabilities, anticipating growth in these areas [9] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the momentum building for 2026, driven by a growing adjusted backlog and improving market conditions [9] - The approval of MediBeacon's Lumitrace injection is expected to unlock access to a significant healthcare market in China [10] - Management noted that while EBITDA may come in slightly below 2024 levels, there is confidence in the growth trajectory for the infrastructure segment [9] Other Important Information - As of September 30, 2025, the company reported a backlog of $1.5 billion and an adjusted backlog of $1.6 billion [19] - The company had total principal outstanding indebtedness of $700.4 million, an increase from $668.3 million at the end of 2024 [23] Q&A Session Summary - There were no questions during the Q&A session, indicating a lack of immediate inquiries from analysts or investors [24]

Core Insights - LandBridge Company LLC reported a strong financial performance for Q3 2025, achieving a revenue growth of 78% year-over-year and 7% quarter-over-quarter, marking the sixth consecutive quarter of revenue and Adjusted EBITDA growth [1][5][9] - The company declared a quarterly cash dividend of $0.10 per share, reflecting its commitment to returning value to shareholders [1][20] - LandBridge completed the acquisition of approximately 37,500 acres, increasing its total holdings to over 300,000 surface acres, which supports its strategy of optimizing and diversifying revenue streams [1][6][8] Financial Performance - Revenues for Q3 2025 were $50.8 million, compared to $28.5 million in Q3 2024, with a net income of $20.3 million and a net income margin of 40% [5][9][11] - Adjusted EBITDA reached $44.9 million, up 79% year-over-year, with an Adjusted EBITDA margin of 88% [5][10][11] - Free Cash Flow for Q3 2025 was $33.7 million, reflecting a Free Cash Flow margin of 66% [5][16][41] Revenue Streams - Surface Use Royalties and Revenue generated $35.0 million in Q3 2025, up from $16.5 million in Q3 2024, driven by increased commercial activity [12] - Resource Sales and Royalties contributed $10.8 million, showing a 2% sequential increase [13] - Oil and Gas Royalties increased by 22% sequentially to $3.3 million, supported by higher net royalty production [14] Recent Developments - The acquisition of 37,500 acres enhances LandBridge's capacity to meet rising demand for high-quality pore space and supports potential alternative energy developments [6][8] - The company finalized the sale of a 3,000-acre solar energy generation project, which has a proposed capacity of up to 250 MW, indicating a strategic move towards alternative energy [7][45] Outlook - LandBridge reaffirms its fiscal year 2025 outlook, expecting Adjusted EBITDA to be between $165 million and $175 million [21]